drugset
drugset / Trial / NCT01892020

Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

NCT01892020 ↗

Phase 4 Completed 161 enrolled Novo Nordisk A/S
RandomizedCrossoverOpen-labelTreatment

Summary

This trial is conducted in Asia. The aim of the trial is to investigate the efficacy and safety of biphasic insulin aspart 50 (BIAsp 50) twice daily versus biphasic human insulin 50 (BHI 50) twice daily, both in combination with metformin, in Chinese subjects with type 2 diabetes mellitus.

Timeline

Start
2013-06
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject biphasic human insulin 50 Unknown — Subcutaneous
Subject biphasic insulin aspart 50 Unknown — Subcutaneous

Indications

type 2 diabetes mellitus